Introduction: Different pharmacological therapies for obesity have become available in the last years. It is important to know their effectiveness in real-world practice and their acceptance among patients.
Objectives: To analyze the anthropometric changes, daily dosis, side effects and treatment withdrawal in patients treated with Liraglutide or Naltrexone/Bupropion in clinical practice.
Material and methods: Retrospective descriptive study. We analysed the percentage of weight loss, side effects and withdrawal causes in patients treated with Liraglutide or Naltrexone/Bupropion after 1, 3, 6 and 12 months.
Results: Hundred patients were included. Baseline characteristics are shown in TABLE. The daily dosis of Liraglutide (mg) were: 0.6 (1.2%), 0.9 (1.2%), 1.2 (25.3%), 1.8 (36.1%), 2.1 (1.2%), 2.4 (13.25%) and 3.0 (20.48%). Daily dose of Naltrexone/Bupropion (mg) were: 8/90 (11.76%), 16/180 (11.76%), 24/270(17.65%) and 32/360 (58.8%). The % of weight loss were: for Liraglutide −3.4%, −6.1%, −6.9% and −7% at 1, 3, 6 and 12 months (P<0.05 for all); for Naltrexone/Bupropion −4.1% and −5.7% at 1 and 3 months (P<0.05) and −5.6% at 6 months (P=0.08). There were no differences in the % of weight loss between high (>1.8 mg) and low (≤1.8 mg) Liraglutide dose. Withdrawal percentage was: 25.3% with Liraglutide, especially due to economic reasons (28.5%), lack of effectiveness (23.8%) or side effects (19%); 29.4% with Naltrexone/Bupropion especially due to side effects (60%) or lack of effectiveness (25%). Side effects were reported in 52.54% patients treated with Liraglutide, the most common being gastrointestinal effects. One patient had depression symptoms that needed treatment and ceased after Liraglutide withdrawal. 66.7% of patients treated with Naltrexone/Bupropion reported side effects, the most common being nausea, headache, dry mouth or dizziness.
|Liraglutide (N=83)||Naltrexone/Bupropion (N=17)|
|Waist Circumference (cm)||116.2±14.0||123.6±13.6|
Conclusions: We observed a significant loss of weight after Liraglutide treatment. Weight loss in Naltrexone/Bupropion group was only significant for the first 3 months. Most of patients in Liraglutide group used <3mg/day, mainly for economic reasons. The percentage of withdrawal was relatively high in both groups, especially due to side effects in Naltrexone/Bupropion and to price or lack of effectiveness in Liraglutide group.
18 - 21 May 2019
European Society of Endocrinology